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Abstract: Her2 overexpression and amplification can be found in a significant subset of 
esophageal adenocarcinomas. The activity of Her2 has been shown to be modulated by 
molecular chaperones such as HSP90. We analyzed expression/amplification data for 
HSP90 and Her2 on 127 primary resected esophageal adenocarcinomas in order to evaluate 
a possible relationship between these two molecules. HSP90 expression determined by 
immunohistochemistry was observed in various levels. Thirty nine (39) tumors (30.7%) 
were classified as Her2-positive according to their immunoreactivity and amplification 
status. There was a significant correlation between HSP90 expression and Her2-status  
(p = 0.008). This could also be demonstrated by quantitative protein expression analysis 
with reverse phase protein arrays (r = 0.9; p < 0.001). Her2-status was associated  
withpT-category (p = 0.041), lymph node metastases (p = 0.049) and tumor differentiation  
(p = 0.036) with a higher percentage of cases with negative Her2 status in lower tumor 
stagesA negative Her2-status was also associated with better survival in univariate and 
multivariate analysis (p = 0.001 and p = 0.014). For HSP90, no associations between 
clinical and pathological parameters were found. The observed association between HSP90 
expression and Her2 suggests a co-regulation of these molecules in at least a subset of 
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esophageal adenocarcinomas. Anti-HSP90 drugs, which recently have been introduced in 
cancer treatment, may also be an option for these tumors by targeting HSP90 alone or in 
combination with Her2. 
Keywords: HSP90; Her2; esophageal adenocarcinoma; immunohistochemistry; RPPA;  
in situ hybridization 
 
1. Introduction 
A significant percentage of adenocarcinomas of the upper gastrointestinal tract show overexpression 
and/or amplification of the membrane-bound tyrosin kinase and proto-oncogene Her2 (ERBB2). Since 
Her2 can be targeted by several drugs such as the monoclonal antibody trastuzumab this finding lead 
to the successful introduction of Her2 directed therapy in gastric cancer [1,2]. We and others have 
demonstrated that esophageal adenocarcinomas show Her2 positivity in a percentage comparable to or 
even higher than gastric cancer [3–5]. Her2 has been shown to interact with HSP90 (heat shock protein 90), 
a molecular chaperone belonging to the group of heat shock proteins [6]. These highly conserved 
molecules are responsible for the correct folding of other proteins, prevention of protein aggregation 
and protein activation [7]. Some data suggest that deregulated HSP90 expression may also support the 
effects of oncogenic Her2 [8] and this may represent a potential mechanism of resistance to Her2 
directed drugs. On the other hand, inhibition of HSP90 may potentiate the effects of anti-cancer drugs 
targeting client proteins of this molecule [9–13].  
The relationship between HSP90 and Her2 has not been investigated for esophageal adenocarcinomas 
so far. We have studied the role of Her2 and recently HSP90—among other molecular chaperones—in 
esophageal adenocarcinomas: overexpression and/or amplification of Her2 were associated with a 
more aggressive biological behavior in a well characterized collection of primary resected tumors. 
Similar expression profiles of molecular chaperones (heat-shock proteins and glucose-regulated proteins) 
were associated with patients’ prognosis in primary resected tumors and response to preoperative 
treatment in patients treated with neoadjuvant chemotherapy before surgery [3,14–17]. For the purpose 
of this correlative and descriptive study we analyzed the raw data of these previous tissue based 
studies, supplemented by some additional expression analysis, in order to evaluate a possible 
association and co-regulation of these molecules. 
2. Experimental  
2.1. Patients and Tissues 
The case collection consisted of 127 formalin fixed, paraffin embedded (FFPE) archival cancer 
tissue from patients with esophageal adencarcinomas who underwent primary surgical resection  
(trans-thoracic or trans-hiatal esophagectomy) between 1993 and 2005 at the Klinikum Rechts der Isar 
of the Technische Universität München (Germany). The resection specimens were processed 
immediately after surgery, i.e., they were opened by a pathologist and fixed in 4.5% buffered formalin 
for 24–48 h. Informed consent from all patients for the use of additional molecular analysis was given 
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at the time of surgery. The use of archival tissue for molecular analysis was approved by the local 
ethical commission (No. 2136/08). The median age of the patients was 62 (range 33–82). Median 
overall survival (OS) was 72 months (95% CI = 34–110). All tumors were reclassified according to the 
current UICC TNM-classification [18]. Tumor grading was done according to the WHO Classification 
of Tumors of the Digestive System [19]. The pathologic characterization of the collective is given in 
Table 1. 
Table 1. Characterization of the case collective of primary resected esophageal adenocarcinomas.  
Parameter n % 
pT category 
pT1 57 44.9 
pT2 24 18.9 
pT3 46 36.2 
Lymph node metastases 
absent 76 59.8 
present 51 40.2 
Distant metastases 
absent 118 92.9 
present 9 7.1 
Grading 
G1 11 8.7 
G2 57 44.9 
G3 59 46.5 
Resection status 
R0 109 85.8 
R1 18 14.2 
total 127  
2.2. Immunohistochemistry 
Immunohistochemistry for Her2 (clone 4B5, Ventana Medical Systems, Inc., Tucson, AZ, USA) 
and HSP90 (Abcam, Cambridge, UK) was performed on formalin-fixed and paraffin-embedded 
(FFPE) tissue on a tissue microarray (TMA) as described before [3,16].  
Her2 immunoreactivity was assessed according to recommendations for Her2 testing in gastric 
carcinoma [20]: immunohistochemistry 3+ staining (Figure 1A) was defined as strong complete  
baso-lateral or lateral membranous staining of cells, irrespective of the percentage of tumor cells, 
visible at low magnification (×2.5–5), immunohistochemistry 2+ as weak to moderate baso-lateral or 
lateral membranous staining visible at ×10–20 magnification, and immunohistochemistry 1+ as weak 
membranous staining visible only with ×40 magnification. The criteria for Her2 assessment were used 
according to the proposal for the application on bioptic tissue [20]. 
The expression of HSP90 (Figure 1C,D) was determined based on the intensity of cytoplasmic 
staining and the percentage of stained tumor cells. Multiplication of scores for intensity of cytoplasmic 
staining and the percentage of stained cells resulted in an immunoreactivity score (IRS). A classification 
into negative—low—high expression was done according to the terciles of the distribution of IRS [16]. 
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Figure 1. Examples of immunohistochemical stainings and in-situ hybridization: (A) Her2 
immunohistochemistry 3+ (positive) ×20; (B) Her2 high level amplification by silver  
in situ hybridization/SISH ×40; (C) HSP90 immunohistochemical low expression ×20;  
(D) HSP90 immunohistochemical high expression; ×20.  
 
2.3. In Situ Hybridization and Definition of Her2 Status 
Data for Her2 amplification were obtained from fluorescence in situ hybridization (FISH) or silver 
in situ hybridization (SISH) analysis [3,21]. A positive Her2 status was defined as immunohistochemical 
3+ and/or amplification determined by ISH with a Her2/cep17 quotient ≥2 (Figure 1B).  
2.4. Protein Extraction, Reverse Phase Protein Arrays and Quantitative Expression Analysis  
For 71 cases additionally quantitative protein expression data generated from reverse phase protein 
array (RPPA) analysis could be included. A detailed description of this approach has been given in 
previous publications [14,16,22]. In brief, immunoreactive protein was extracted from freshly cut 
sections of FFPE tissue, which then were processed in 100 µL of extraction buffer EXB Plus according 
to the supplier’s recommendations (Qproteome FFPE Tissue Kit, Qiagen, Hilden, Germany). Protein 
concentrations were determined using the Bradford protein assay according to the manufacturer’s 
instructions (BioRad, Hercules, CA, USA). Probing for β-actin by western blot was done in order to 
verify the success of the protein extraction and the suitability of the material for later reverse phase 
protein array (RPPA) analysis.  
RPPAs were generated using the Calligrapher MiniArrayer (BioRad) in accordance with the 
manufacturer’s instructions. Three replicates per lysate were applied in various dilutions to a 
nitrocellulose-coated glass slide (Grace Bio-Labs, Bend, OR, USA) in order to obtain a total of 18 data 
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points per sample. Peroxidase blocking was performed according to the manufacturer’s instructions 
(Dako, Glostrup, Denmark). Immunodetection was performed similar to a western blot (antibodies: 
HSP90: Abcam, Cambridge, UK; Her2: Dako; pHer2
Tyr1248
: Invitrogen, Carlsbad, CA, USA). In parallel, 
staining with Sypro Ruby Protein Blot Stain (Molecular Probes, Eugene, OR, USA) was done for the 
estimation of the total protein amount. The TIFF images for the antibody-stained slides and Sypro 
Ruby-stained slides were analysed with MicroVigene 3.5.0.0 software (VigeneTech, Carlisle, MA, 
USA). The MicroVigene signal-intensity points (MVS) were calculated by the integral of a logistic 
four-point fit model, matched optimally to the 18 data points that had been obtained. 
2.5. Statistical Analysis 
IBM SPSS 21.0 Statistics statistical software (SPSS Inc., Chicago, IL, USA) was used for statistical 
analysis. Associations between expression and amplification data and pathological features were given 
in crosstabs and were evaluated with X
2
 test. For survival analysis, Kaplan-Meier estimates, log rank 
tests and Cox’s proportional hazards regression analysis were used. All tests were 2-sided, and the 
significance level was set at 0.05. 
3. Results 
3.1. HER2 Immunohistochemistry and in Situ Hybridization 
Seventy four (74) tumors (58.3%) showed no Her2 immunoreactivity, 25 tumors (19.7%) had an 
immunoscore of 1+, 13 cases (10.2%) showed 2+ immunoreactivity and 15 cases (11.8%) 3+. Using 
the criteria mentioned above, which included in-situ hybridization of all tumors, 88 tumors (69.3%) 
were classified as Her2 negative, and 39 tumors (30.7%) as Her2 positive.  
3.2. HSP90 Immunohistochemistry 
In 61 cases (48.0%) there was no immunoreactivity for HSP90. Forty four (44) tumors (34.6%) 
showed low HSP90 expression (IRS score 1–4) and 22 tumors (17.3%) showed high HSP90 expression 
(IRS score > 4). 
3.3. Quantitative Protein Expression (RPPA) 
Median quantitative expression of Her2 (Her2/SyproRuby) was 675 (range; 188–9058) and of 
pHer2 (pHer2/SyproRuby) was 726 (range; 161–3100). Median quantitative HSP90 expression 
(HSP90/Sypro Ruby) was 775 (range; 207–3245). 
3.4. Association between Her2 and HSP90  
There was a correlation between HSP90 expression assessed by immunohistochemistry and Her2 
status (p = 0.008; Table 2): the rate of Her2 positive tumors in relation to HSP90 expression was 28% 
for HSP90 negative tumors. 69% of Her2 tumors showed HSP90 expression (44% HSP90 low tumors 
and 28% HSP90 high tumors). In contrast, the percentage of Her2 negative tumors in relation to 
HSP90 expression was decreasing from 57% (HSP90 negative tumors), over 30% (HSP90 low tumors) 
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to 13% (HSP90 high tumors). The association between HSP90 and Her2 expression could also be 
demonstrated by quantitative RPPA analysis: Her2 vs. HSP90: Spearman-rho = 0.574; pHer2 vs. 
HSP90: Spearman-rho = 0.791 (p < 0.001 each; Figure 2). Her2 and pHer2 expression levels showed a 
highly significant correlation as well (Spearman-rho = 0.531; p ≤ 0.001). Interestingly, tumors with 
HSP90 immunoreactivity had slightly, but not significant higher Her2 levels by RPPA (p = 0.059), but 
not HSP90 or pHer2 levels (p = 0.432 and p = 0.486). Between Her2 status and RPPA expression data, 
no correlations were found. 
Table 2. Correlation between HSP90 expression and Her2 status.  
 
Her2 Status 
Total p-value 
Negative Positive 
HSP90 expression 
negative 50 11 61 
0.008 
low 27 17 44 
high 11 11 22 
Total 
 
88 39 127 
Figure 2. Scatterplot with RPPA data for quantitative relative Her2 expression and  
HSP90 expression.  
 
3.5. Clinicopathological Parameters and Survival Analysis 
There were no significant associations between pathologic features (pT, pN category, grading) and 
HSP90 (Table 3). Her2 positivity was associated with pT category (p = 0.041), lymph node metastases 
(p = 0.049) and tumor differentiation (p = 0.036; Table 4), in particular the percentage of Her2 
negative tumors was higher in tumors with lower pT-category and without lymph node metastases as 
compared to Her2 positive tumors. Moreover, there were no well differentiated tumors (G1) with Her2 
positivity. A negative Her2 status was also associated with better survival in univariate (p = 0.001; 
Figure 3A) and multivariate analysis (p = 0.005). This was not the case for HSP90 (Figure 3B; Table 5). 
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Table 3. Correlation between HSP90 expression and pathologic characteristics.  
Parameter 
HSP90 Expression 
p-value 
Negative Low High 
pT category 
pT1 30 20 7 
0.232 pT2 9 7 8 
pT3 22 17 7 
lymph node mets. 
absent 40 23 13 
0.389 
present 21 21 9 
distant mets. 
absent 57 41 20 
0.921 
present 4 3 2 
grading 
G1 8 3 0 
0.246 G2 29 17 11 
G3 24 24 11 
total 127 61 44 22  
Table 4. Correlation between Her2 status and pathologic characteristics.  
Parameter 
Her2 Status p-value 
Negative Positive  
pT category 
pT1 46 11 
0.041 pT2 14 10 
pT3 28 18 
lymph node metastases 
absent 58 18 
0.049 
present 30 21 
distant metastases 
absent 82 36 
1.0 
present 6 3 
grading 
G1 11 0 
0.036 G2 35 22 
G3 42 17 
total 127 88 39  
Table 5. Multivariate analysis of prognostic relevant factors.  
Factor Exp(B) 
95% CI for Exp(B) 
p-value 
Min Max 
pTcategory 1.292 0.824 2.025 0.264 
lymph node mets 2.235 1.07 4.67 0.032 
distant mets 1.69 0.711 4.016 0.235 
grading 1.218 0.736 2.016 0.443 
resection status 3.172 1.586 6.34 0.001 
Her2 status 2.028 1.152 3.57 0.014 
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Figure 3. (A) Her2 status and overall survival; (B) HSP90 expression and overall survival.  
 
4. Discussion 
The results of our analyses demonstrate an association between the expression of HSP90 and Her2 
amplification/expression in esophageal adenocarcinomas which may present at least in a subset of 
tumors. This could be observed by immunohistochemistry and by quantitative protein expression 
analysis with reverse phase protein arrays (RPPA). In contrast to Her2, where an association between 
tumoral Her2 positivity and unfavorable clinical course had been reported before [3], no correlation 
between HSP90 alone and clinical and pathological parameters was found. 
The rate of Her2 overexpressing or amplified esophageal adenocarcinomas [23] is comparable to 
gastric [2,24] and breast cancer [25]. In contrast to breast cancer, data about the prognostic impact of 
Her2 in gastrointestinal tumors are not conclusive. Although only investigated in retrospective 
analyses, Her2 positivity is presumed to be predictive for anti Her2-directed therapy, which recently 
successfully has been introduced in the treatment of metastasized gastric and gastro-esophageal 
adenocarcinomas [1]. The activity of Her2 has been shown to be influenced and partly controlled by so 
called ―molecular chaperones‖. These molecules assure accurate folding of other proteins thereby 
assisting in the maintenance of cellular integrity and homeostasis [26,27]. Heat shock proteins (HSPs) 
which are subdivided into several classes according to their molecular weight act as classical 
chaperones under normal conditions. Interestingly, deregulated activity of HSPs has been found in 
cancer cells. This may be caused by intrinsic malignant deregulatory effects but also by the altered 
interaction with other oncogenic molecules [6,28]. HSP90 is one of the most abundant cellular HSPs.  
Molecules such as Her2, EGFR, VEGFR, ALK, AKT, p52, cyclin D1, Met, Cdk4, HIF-1α or 
MMP2 which play important roles as oncogenes and are involved in essential pathways of cancer are 
described to be client proteins of HSP90 (for review [10,13]).  
This association caused interest on the impact HSP90 as potential anti-tumoral target. Inhibition of 
HSP90 may represent a combinatorial attack on multiple oncogenic pathways. In the last years, the 
development of anti-HSP90 directed drugs and inhibitors has rapidly moved forward. Geldanamycin 
A B
Cancers 2014, 6 1390 
 
 
derivatives (e.g., 17-AAG) were the first substances that showed that HSP90 is a druggable target for 
cancer therapy. Second generation and synthetic HSP90 inhibitors have improved pharmacological 
properties and safety profiles [13,29]. Anti-HSP90 therapy may be applied alone or in combination 
with other cytotoxic or directed therapies. Although up to date no agent has been approved for use in 
the clinical practice, targeting HSP90 is considered as exciting and promising new treatment approach 
and HSP90 inhibitors have been tested in many preclinical and clinical studies. A detailed description 
of these various studies would be beyond the scope of this paper, so we would like to refer to recent 
reviews and meta-analyses [10,13]. In brief, besides in ALK-rearranged NSCLC the highest efficacy 
for HSP90 inhibition so far has been reported for Her2-positive breast cancer: for example, HSP90 
inhibition resulted in a dose-dependent and complete degradation of active (phosphorylated) HER2 
and EGFR in Her2 overexpressing cell lines [30]. A novel HSP90 inhibitor, CH5164840 showed 
significant antitumor efficacy against gastric and breast cancer models which was even more enhanced 
when combined with HER2-targeting agents [31]. A combination therapy with the HSP90 inhibitor  
17-AAG and trastuzumab showed significant anticancer activity in patients with HER2-positive 
metastatic breast cancer progressing on trastuzumab in a phase II study [32]. Basing on such results, 
HSP90 targeting alone or in combination with Her2 directed therapy is regarded as a promising novel 
approach for the treatment of breast cancer, which also may be a potentially successful way to 
overcome acquired or intrinsic trastuzumab resistance. Moreover, this may also be transferred onto 
other Her2 positive tumors, such as the subset of gastrointestinal adenocarcinomas with Her2 
overexpression or amplification. On the tissue level, however, there are only scarce data about HSP90 
and Her2 in human malignancies. Recently, we have reported a strong correlation between HSP90 and 
Her2 expression in gastric carcinomas [33] and colon carcinomas [34] which is in line with the 
observations of the present study. To our knowledge, other tissue based studies about the association of 
these molecules in other tumor types, however, are not available yet. 
5. Conclusions  
The results of our analyses may contribute to the learning about the biology of HSP90 and its client 
proteins, especially supporting an association between Her2 and HSP90 expression at least in a subset 
of cases on the tissue level. They warrant further functional investigation about the interaction of 
HSP90 and Her2 in gastrointestinal carcinomas both in vitro and in- or ex vivo. Basing on these data, 
the rationale for HSP90 as a potential targetable molecule may offer interesting alternative  
therapeutic options for gastrointestinal tumors, especially for Her2 positive gastric and esophageal 
adenocarcinomas [29,35].  
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